Sotera Health (NYSE:SHC – Get Rating) was upgraded by analysts at JPMorgan Chase & Co. from an “underweight” rating to a “neutral” rating in a report released on Monday, MarketBeat reports. The brokerage presently has a $18.00 price objective on the stock, up from their previous price objective of $6.00. JPMorgan Chase & Co.‘s price objective would suggest a potential upside of 7.02% from the company’s current price.
A number of other analysts have also weighed in on the stock. Barclays raised shares of Sotera Health from an “underweight” rating to an “overweight” rating and increased their price objective for the stock from $6.00 to $22.00 in a research report on Tuesday, January 10th. The Goldman Sachs Group reduced their price objective on shares of Sotera Health from $9.00 to $8.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 23rd. Citigroup downgraded shares of Sotera Health from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $25.00 to $9.00 in a research note on Wednesday, October 5th. Wolfe Research upgraded shares of Sotera Health from a “peer perform” rating to an “outperform” rating and set a $25.00 target price on the stock in a research note on Tuesday, January 10th. Finally, Royal Bank of Canada dropped their target price on shares of Sotera Health from $25.00 to $8.00 and set an “outperform” rating on the stock in a research note on Thursday, November 3rd. Four investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $18.89.
Sotera Health Trading Down 2.8 %
Shares of Sotera Health stock opened at $16.82 on Monday. The company has a market capitalization of $4.75 billion, a P/E ratio of 38.23 and a beta of 1.30. The company has a debt-to-equity ratio of 2.97, a quick ratio of 2.74 and a current ratio of 3.00. The company has a fifty day moving average of $10.21 and a 200 day moving average of $12.06. Sotera Health has a fifty-two week low of $5.78 and a fifty-two week high of $24.90.
Institutional Trading of Sotera Health
Institutional investors have recently modified their holdings of the stock. BNP Paribas Arbitrage SNC acquired a new stake in shares of Sotera Health in the third quarter valued at about $37,000. Bridgefront Capital LLC acquired a new position in Sotera Health during the third quarter worth about $72,000. Fox Run Management L.L.C. acquired a new position in Sotera Health during the third quarter worth about $75,000. Cipher Capital LP acquired a new position in Sotera Health during the third quarter worth about $77,000. Finally, Ensign Peak Advisors Inc boosted its position in Sotera Health by 156.6% during the third quarter. Ensign Peak Advisors Inc now owns 13,290 shares of the company’s stock worth $91,000 after acquiring an additional 8,110 shares during the last quarter. Institutional investors and hedge funds own 87.21% of the company’s stock.
About Sotera Health
Sotera Health Company provides sterilization, and lab testing and advisory services in the United States, Canada, Europe, and internationally. The company's sterilization services include gamma and electron beam irradiation, and EO processing; Nelson Labs comprise microbiological and analytical chemistry testing; and advisory services for medical device and biopharmaceutical industries.
- Get a free copy of the StockNews.com research report on Sotera Health (SHC)
- Qualcomm Gets a Boost from Analysts, but is it Time to Buy?
- EVgo Stock is Charged Up to Ride the EV Adoption Wave
- High-Yield, Deep-Value Verizon Puts In A Bottom
- Can Coty Stock Emerge in 2023 With Upside
- Should You Bet Against The Nasdaq 100 With This Inverse ETF?
Receive News & Ratings for Sotera Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sotera Health and related companies with MarketBeat.com's FREE daily email newsletter.